Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 16;12:557994. doi: 10.3389/fimmu.2021.557994

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhao, Wang, Wang, Dai, Wang and Ma

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Role of phenotype in predicting anti-tumor drugs response and peri-tumoral edema. (A) The immune-L phenotype was more sensitive to bortezomib (P < 2.2e-16), cisplatin (P = 5.3e-15), docetaxel (P < 2.2e-16), lapatinib (P < 2.2e-16), rapamycin (P = 3.3e-8); the immune-H phenotype was more sensitive to paclitaxel (P = 3.1e-10) and sorafenib (P = 0.0053). (B) Representative images of the differences in the extent of peri-tumoral edema in TCGA cohort patients. Immune-H phenotype significantly possessed more-severe edema than immune-L.